Recently, our animal study showed that sotagliflozin (SOTA), an approved sodium glucose cotransporter 1 and 2 (SGLT1/2) inhibitor for diabetes, not only improves the cardiac function of mice with MI, but also ameliorates the depression-like behaviors in the mice (127). The gene discussed is SLC5A1; the disease is myocardial infarction.